Granules India Limited Announces That Gagillapur Facility Located At Hyderabad, Telangana, India Completes the U.S. Food and Drug Administration's Pre-Approval Inspection from January 9, 2023 to January 13, 2023

Granules India Limited announced that Gagillapur facility located at Hyderabad, Telangana, India has completed the U.S. Food and Drug Administration's Pre-Approval Inspection (PAI) from January 9, 2023 to January 13, 2023 with 3 observations and the Company will respond to these observations within the stipulated time period. Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).